<DOC>
	<DOCNO>NCT02140320</DOCNO>
	<brief_summary>RV1729 new medicine develop potential treatment asthma smoke related lung disease ( also know chronic obstructive pulmonary disease - COPD ) . The objective study investigate safety , tolerability pharmacokinetics single dos RV1729 repeat dos RV1729 28 day .</brief_summary>
	<brief_title>A Study Investigate Safety , Tolerability Pharmacokinetics Single Repeat Doses RV1729 28 Days</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Be man woman 18 60 year age , inclusive , time signing informed consent . Cohorts 1 , 2 &amp; 3 woman childbearing potential must document menstrual period prior first dose willing use 2 form appropriate method contraception screen 4 month final dose RV1729 , OR Women nonchildbearing potential must spontaneously amenorrhoeic least 1 year permanently sterilise , OR If man , must willing able use one contraception method list protocol agree donate sperm screen 4 month final dose RV1729 Women must agree donate egg ( ovum , oocytes ) screen least 6 month final dose RV1729 Sign inform consent document indicate understand purpose procedure require study willing participate study . Body mass index 19 30 kg/m2 body weight less 50 kg . Vital sign assessment within normal range Have 12lead ECG record consistent normal cardiac function Capable comply study restriction procedure include ability use study inhaler correctly Cohorts 1 , 2 &amp; 4 ( healthy volunteer ) Healthy determine physician , base full medical evaluation include medical history , physical examination laboratory test . Prebronchodilator spirometry reading ( FEV1 FVC ) ≥80 % predict value FEV1/FVC ratio &gt; 0.7 Not take prescription medication 14 day prior screen agree use prescription medication throughout duration study ( exception use contraceptives hormone replacement therapy ) . Not take overthecounter medication herbal medication 14 day prior screen throughout study . Cohort 3 ( asthma patient ) Documented history asthma , least 6 month prior screen currently treat daily inhaled corticosteroid without long act betaagonist ( LABA ) Have diagnosis asthma . This confirm bronchodilator reversibility screen Have prebronchodilator FEV1 ≥60 % ≤85 % predict normal value Have stable asthma base exacerbation require change therapy 12 week hospitalisation visit accident emergency asthma 12 month prior screen . Not clinical abnormality laboratory parameter outside reference range . Not take prescription medication 14 day prior screen agree use prescription medication throughout duration study except use contraceptive hormone replacement therapy treatment asthma Not take overthecounter medication herbal medication 14 day , antihistamine 7 day prior screen visit agree refrain taking medication throughout study . Upper low respiratory tract infection within 4 week screen Clinically significant abnormal value haematology , clinical chemistry urinalysis screen Day 1 Has history current sign symptom severe , progressive , uncontrolled renal , hepatic , hematological , gastrointestinal , endocrine , pulmonary , cardiac , neurologic , cerebral , psychiatric disease . History , reason believe subject history drug alcohol abuse within past 5 year . Positive test alcohol drug abuse , include cannabinoids , alcohol , opiates , cocaine , amphetamine , benzodiazepine barbiturate screen Day 1 History clinically significant allergy , opinion Investigator Medical Monitor , would contraindicate participation . Subjects know suffer hayfever , allergy , may require antihistamine therapy course study . Known allergy study drug excipients formulation previously expose RV1729 . Donated blood blood product substantial loss blood ( 500 mL ) within 3 month intention donate blood blood product study . Received experimental drug use experimental medical device within 3 month within period le 10 time drug 's halflife , whichever longer , first dose study drug schedule . If woman positive serum pregnancy test screen positive urine pregnancy test Day 1 , pregnant , breastfeed plan become pregnant study . Liver function test result &gt; 1.5 x ULN ( upper limit normal ) Screening Day 1 . Positive test human immunodeficiency virus ( HIV ) 1 2 antibody , hepatitis B virus ( HBV ) infection hepatitis C antibody . History smoking use nicotinecontaining substance within previous 6 month , positive carbon monoxide test screen Day 1 ( smoke history ≥ 10 pack year ) . Preplanned surgery procedure would interfere conduct study . Employee Investigator study centre , direct involvement propose study study direction Investigator study centre , well family member employee Investigator . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . History regular alcohol consumption within 6 month study . The subject unable unwilling comply fully study protocol . Subject mentally legally incapacitate . Unable unwilling undergo multiple venepuncture procedure subject poor access vein suitable cannulation . Any reason Investigator considers make subject unsuitable participate . Cohorts 1 , 2 &amp; 4 ( healthy volunteer ) Any chronic illness clinically relevant abnormality identify screen medical assessment , laboratory test ECG Cohort 3 ( asthma patient ) Administration oral , injectable dermal steroid leukotriene modifier within 3 month intranasal steroid within 1 week screen visit . Has ever episode lifethreatening asthma define respiratory arrest , intubation asthma , intensive care unit admission asthma . Any acute chronic illness clinically relevant abnormality asthma identify screen medical assessment , laboratory test ECG . Has severe asthma base Investigator assessment and/or use prohibit asthma medication . Cohort 4 ( healthy volunteer ) Women child bearing potential</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>